-
Epstein-Barr Virus May Help Spark Multiple Sclerosis, Study Finds
A new study from the University of Basel reveals how Epstein-Barr virus can disable immune safeguards in the brain, allowing rogue B cells to trigger early MS-like damage. The work offers a concrete biological explanation for one way multiple sclerosis may get its start.
-
Cholera Bacterial Toxin Shows Promise Against Colorectal Cancer
A purified toxin from cholera bacteria slowed colorectal cancer growth in mice while sparing healthy tissue. The findings could inspire a new class of treatments that turn bacterial weapons into cancer-fighting tools.
-
How a Common Virus and a Gene Variant Team Up to Trigger MS
A University of Zurich team has uncovered how a common virus and a specific genetic variant can jointly spark multiple sclerosis. The work helps explain who gets MS and points toward new ways to prevent or treat the disease.
-
Georgetown Team Boosts Cancer-Fighting T Cells With PARP Drugs
Georgetown University researchers have found a way to reprogram key immune cells so they remember and attack cancer more powerfully and for longer. The lab discovery could expand the use of existing PARP drugs and strengthen cutting-edge immunotherapies.
-
Stem Cell Advance Brings Off-the-Shelf ‘Living Drugs’ Closer to Reality
UBC researchers have figured out how to reliably grow a crucial kind of immune cell from stem cells. The advance could make powerful cell therapies cheaper, faster and more widely available.
-
Tiny Eye Cell ‘Twitch’ Could Transform Early Blindness Detection
An NTU Singapore-led team has, for the first time, captured a tiny mechanical twitch in the eye’s night-vision cells as they detect light. The breakthrough could pave the way for earlier, non-invasive detection of diseases that cause blindness.
-
Gene Therapy ‘Off Switch’ Aims to Ease Pain Without Addiction
Researchers at the University of Pennsylvania and collaborators have engineered a brain-targeted gene therapy that dials down pain in mice without activating reward pathways linked to addiction. The work could lay the groundwork for non-addictive treatments for chronic pain.
-
How a Tumor-Suppressing Protein Could Boost Head and Neck Cancer Immunity
Researchers at MD Anderson have identified a tumor-suppressing protein that is shut down by excess glutamine in head and neck cancers, blunting the immune response. Blocking glutamine metabolism restored immune activity in preclinical models, pointing to a new way to help resistant tumors respond to treatment.
-
Breast Cancer Drug Shows Promise Against Deadly Leukemia
Oregon Health & Science University researchers have identified a drug duo that could help people with acute myeloid leukemia overcome treatment resistance. By pairing a standard leukemia drug with a breast cancer medicine, the team saw stronger, longer-lasting anti-cancer effects in lab and animal studies.
-
‘Molecular Glue’ Drug Strategy Targets Resistant Lung Cancer
University of Michigan researchers have found a way to use a “molecular glue” to stabilize a tumor-suppressing protein and shrink drug-resistant lung tumors in mice. The approach could help extend the effectiveness of existing treatments for KRAS-mutant cancers.
